Skip to main content
Ingredients/Compound/Adrafinil

Adrafinil.

Wakefulness promoter that converts to modafinil in your liver. Converts to modafinil in your liver. Promotes wakefulness without the jitters of stimulants.

Extensively studiedResearch depth300 to 600mgDaily amount90Studies read

Reviewed March 2026

ADCompound
AdrafinilIngredientMD
Category
Compound

Also filed under
WakefulnessFocusAlertness

What Adrafinil is, and what it does.

Does it work
Occasionally. Works well but liver concerns mean it's not for regular use. Modafinil itself is safer.
How much to take
300-600mg on occasion. Not daily. Give your liver a break.
Time to feel it
Wakefulness builds over about 45 to 90 minutes, because the liver has to convert it first, and it carries through most of a working day.
The first dose
Alert and focused within an hour. Effects last 6-8 hours. Don't take after noon.
With regular use
Not recommended for long-term use. Save it for when you really need it.
How well tolerated
Stresses the liver with conversion. Occasional use only. Regular use not advised.
How it feels
Clear-headed wakefulness. Not stimulating or euphoric. Just... awake.
The overlooked benefit
The metabolite induces one drug-clearing enzyme and blocks another, so it can change how your body handles other things you take. Worth raising with a pharmacist.

300 to 600mg a day is where Adrafinil works.

How much to take a dayLimited data
Up to 300mgA supporting role. Common in blends where this is one active among several.
300 to 600mg
Daily maintenanceThe everyday amount, and where most daily supplements sit. This is the one you take month after month.
Above 900mgPast what the research covers. More capsules rather than more effect.
MORE EFFECT ↑0300mg600mg plateauDAILY DOSE →
The shaded band is where the dosing trials landed.

Source: Milgram et al. Pharmacol Biochem Behav 2000; nootropic community data

The proof, claim by claim.

These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.

Extensively studied.

Adrafinil has solid evidence. Based on 90+ studies.

  • daytime wakefulness during extended wakingRandomised trial
  • vigilance and sustained attentionRandomised trial
  • conversion in the liver to an active wake-promoting metaboliteNarrative review
  • alertness in older adultsRandomised trial
  • dopamine transporter binding as the wake-promoting routeAnimal study
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AI90 studies readLabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AI90 studies readLabs test. IngredientMD verifies.

Questions people ask about Adrafinil.

When should I take it?
Timing matters less than consistency. Pick a time that works for you and take it daily.
Can I take it with other supplements?
Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
Any side effects to watch for?
Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Who benefits most from this?
Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Pairs well with14 on file

Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.

Adrafinil + Modafinilprecursor to active compound

Adrafinil is hydrolysed in the liver to modafinil, which carries the wakefulness activity. Anything that shifts hepatic handling changes how much of the active form appears.

Adrafinil + Caffeineadditive arousal by separate routes

Caffeine blocks adenosine receptors while the adrafinil route acts through catecholamine and orexin signalling, so alerting effects add up. Formulators stagger the two rather than stacking full doses together.

Adrafinil + L-theanineEstablished pharmacology of the two constituents, no combination trial for this pair

L-theanine is commonly stacked with wake-promoting compounds to soften the jittery edge that stimulants can produce, an effect studied mainly alongside caffeine rather than adrafinil. The two act by unrelated routes: theanine on glutamate and GABA receptor signalling, adrafinil through its conversion product on catecholamine reuptake. No study has measured the pair together, so this is a mechanistic proposal.

Adrafinil + L-tyrosineEstablished catecholamine biochemistry

Tyrosine is the amino acid precursor of dopamine and noradrenaline, and its availability limits catecholamine synthesis when turnover is high. Adrafinil's active metabolite raises synaptic catecholamine levels by slowing reuptake rather than by making more, so the two act at different points in the same pathway. Precursor supply matters more under sustained demand than at rest.

Adrafinil + MelatoninEstablished opposing physiology

Melatonin signals biological night and shortens the time to fall asleep, while adrafinil's metabolite promotes wakefulness with a long duration of action. Taken in the same evening the two work against each other on the same sleep-wake axis. The timing conflict is the point of the flag.

Adrafinil + Valerian rootEstablished opposing physiology

Valerian is used for its sedating properties and adrafinil for the opposite effect on arousal. Combining them within the same window gives contradictory signals to the same system. Neither cancels the other cleanly, since their durations of action differ.

Adrafinil + AshwagandhaOpposing effects on arousal

Ashwagandha is taken for calming and evening use in many formulas, which runs counter to a compound taken to extend alertness. Whether the two meaningfully offset each other has not been measured. Separating them by time of day is the usual practical handling.

Adrafinil + Rhodiola roseaOverlapping effects on alertness

Rhodiola is used for subjective alertness under fatigue, the same broad territory as adrafinil's metabolite. Stacking two arousal-promoting agents adds their effects on sleep latency later in the day. No trial has combined them.

Adrafinil + Green tea extractCaffeine content of the extract

Standardised green tea extracts often carry meaningful caffeine unless specifically decaffeinated, so combining one with a wake-promoting compound stacks two stimulant loads that a label may not make obvious. The additive part is straightforward pharmacology of the caffeine. Reading the caffeine content on the extract is what makes the total dose knowable.

Adrafinil + NACEstablished hepatic glutathione biochemistry

Adrafinil is hydrolysed in the liver, and its use has been associated with raised liver enzyme readings, which are markers of hepatocyte turnover rather than outcomes in themselves. N-acetylcysteine supplies cysteine for glutathione synthesis, the main hepatic conjugation defence. The pairing is mechanistic reasoning about the organ that does the conversion, not a measured interaction.

Adrafinil + Milk thistle (silymarin)Traditional hepatic-support pairing, no combination study

Silymarin is the conventional companion in stacks where the liver does substantial metabolic work on the main compound. It has not been tested alongside adrafinil, and it does not change the conversion step. Anyone taking a compound with reported liver enzyme elevations should have that monitored by a clinician rather than assume a botanical covers it.

Adrafinil + Alpha-GPCCommon stack pairing, no combination study

Alpha-GPC supplies choline for acetylcholine synthesis, a separate transmitter system from the catecholamine reuptake route involved in adrafinil's action. They are frequently combined in consumer stacks on that complementarity argument. No study has measured the combination.

Adrafinil + MagnesiumEstablished physiology of stimulant-related sleep disruption

Magnesium is commonly added to stimulant-containing routines for its role in normal muscle relaxation and sleep quality. It does not alter adrafinil's conversion or clearance. The pairing is practical rather than pharmacological.

Adrafinil + TaurineCommon co-formulation with stimulants

Taurine appears alongside caffeine in energy formulations and acts as an inhibitory modulator at glycine and GABA-A receptors. Any smoothing effect on a wake-promoting compound is inferred from that receptor role, not measured with adrafinil. The evidence is mechanistic only.

Who should be cautious

Talk to a doctor before taking Adrafinil if any of these apply to you: liver stress, not for daily use, synthetic. These are flags to check first, not effects Adrafinil is known to cause.

Not medical advice. Show the label to your pharmacist.

What Adrafinil actually does.

Established

Adrafinil is a prodrug: it is hydrolysed in the liver to modafinil, and the pharmacological effects attributed to it are those of that metabolite.

Established

Because the conversion step has to happen before the active metabolite appears, the onset after an oral dose of adrafinil is slower than after the same molar amount of modafinil.

Established

Modafinil binds the dopamine transporter and slows dopamine reuptake, and its wake-promoting action is lost in animals lacking that transporter; the compound also acts on orexin and histamine signalling in wake-regulating regions.

Established

Hydrolysis of adrafinil also yields modafinil acid, an inactive metabolite that is cleared renally.

Made in a lab, 6 steps on record

Where Adrafinil comes from.

It is built in a chemical plant from simple industrial starting materials in a handful of reaction steps, then crystallised, dried and either bottled as powder or filled into capsules. Nothing about it grows.

Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.

Starts as
Petrochemical intermediates

The route starts from benzhydryl building blocks, typically benzhydrol or a benzhydryl halide, together with a thioglycolic acid derivative. None of these has a botanical or animal source.

Converted by
Thioether formation

The benzhydryl group is joined to the sulfur of the thioglycolate fragment, giving a benzhydrylthioacetic acid intermediate.

Converted by
Sulfoxide oxidation

The sulfur is oxidised to the sulfoxide with a controlled oxidant. Over-oxidation to the sulfone is the side reaction the process is designed to limit.

Converted by
Hydroxamic acid formation

The carboxylic acid is converted to the hydroxamic acid, the feature that distinguishes adrafinil from modafinil and the group removed in the liver during activation.

Purified by
Crystallisation

The crude product is recrystallised from solvent to remove the sulfone and unreacted intermediates, then dried. Residual solvent and related-substance limits are what a certificate of analysis reports.

Ends up as
Milling and encapsulation

The dried crystals are milled to a consistent particle size and either sold as powder or blended with a flow agent and filled into capsules.

Manufacturers rarely publish the specific oxidant or solvent system used, so the related-substance profile on a certificate of analysis is the only practical window into how the batch was made.

The forms it comes in.

Adrafinil powderThe hydroxamic acid as a white crystalline powder, poorly soluble in water and noticeably bitter.Fits Users who weigh their own doses and want no capsule excipients.Trade-off Bitter enough to be unpleasant on the tongue, and accurate dosing of a small mass depends on a scale with adequate resolution.
Adrafinil capsulesThe same free base filled into a gelatin or HPMC capsule, usually with a flow agent such as microcrystalline cellulose or magnesium stearate.Fits Fixed unit dosing without handling loose powder or tasting it.Trade-off The dose is fixed at whatever the capsule holds, and the capsule shell adds a short delay before the powder disperses.
Side effects reported to the FDA

Problems people have reported.

Read this carefully. These are 134 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Adrafinil is, not how risky it is. A report is not proof Adrafinil caused anything. It is a signal of what to watch for, nothing more.

Drug Interaction
4
Insomnia
4
International Normalised Ratio Increased
4
Disorientation
3
Fall
3
Somnolence
3

Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.